J. Abelous and E. Barbier, Les substances hypotensives de l'urine humaine normale, CR Soc Biol, vol.66, pp.511-520, 1909.

E. Frey and H. Kraut, Ein neues Kreislaufhormon und seine Wirkung, Naunyn-Schmiedebergs Archiv f??r Experimentelle Pathologie und Pharmakologie, vol.175, issue.Hft. 3/4, pp.1-56, 1928.
DOI : 10.1007/BF01955578

M. Rocha-e-silva, W. Beraldo, and G. Rosenfeld, Bradykinin, a hypotensive and smooth muscle stimulating factor released from plasma globulin by snake venoms and by trypsin, Am. J. Physiol, vol.156, pp.261-273, 1949.

J. Björkqvist, A. Jämsä, and T. Renné, Plasma kallikrein: the bradykinin-producing enzyme, Thrombosis and Haemostasis, vol.110, issue.3, pp.399-407, 2013.
DOI : 10.1160/TH13-03-0258

R. Pixley, R. Espinola, B. Ghebrehiwet, K. Joseph, A. Kao et al., Interaction of high-molecular-weight kininogen with endothelial cell binding proteins suPAR, gC1qR and cytokeratin 1 determined by Surface Plasmon Resonance (BiaCore), Thrombosis and Haemostasis, vol.105, issue.6, pp.1053-1059, 2011.
DOI : 10.1160/TH10-09-0591

Z. Shariat-madar, F. Mahdi, and A. Schmaier, Identification and Characterization of Prolylcarboxypeptidase as an Endothelial Cell Prekallikrein Activator, Journal of Biological Chemistry, vol.277, issue.20, pp.17962-17969, 2002.
DOI : 10.1074/jbc.M106101200

K. Joseph, B. Tholanikunnel, and A. Kaplan, Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of factor XII, Proc. Natl
DOI : 10.1073/pnas.022626899

R. Pixley and R. Colman, [4] Factor XII: Hageman factor, In: Laszlo Lorand KGM, éditeur. Methods in Enzymology, pp.51-65, 1993.
DOI : 10.1016/0076-6879(93)22007-3

J. Johne, C. Blume, P. Benz, M. Pozgajová, M. Ullrich et al., Platelets promote coagulation factor XII-mediated proteolytic cascade systems in plasma, Biological Chemistry, vol.387, issue.2, pp.173-178, 2006.
DOI : 10.1515/BC.2006.023

C. Puy, E. Tucker, Z. Wong, D. Gailani, S. Smith et al., Factor XII promotes blood coagulation independent of factor XI in the presence of long-chain polyphosphates, Journal of Thrombosis and Haemostasis, vol.147, issue.Suppl. 1, pp.1341-1352, 2013.
DOI : 10.1111/jth.12295

M. Ginsberg, B. Jaques, C. Cochrane, and J. Griffin, Urate crystal--dependent cleavage of Hageman factor in human plasma and synovial fluid, J. Lab. Clin. Med, vol.95, pp.497-506, 1980.

A. Kaplan and B. Ghebrehiwet, The plasma bradykinin-forming pathways and its interrelationships with complement, Molecular Immunology, vol.47, issue.13, pp.2161-2169, 2010.
DOI : 10.1016/j.molimm.2010.05.010

U. Semba, Y. Shibuya, H. Okabe, I. Hayashi, and T. Yamamoto, Whale High-Molecular-Weight and Low-Molecular-Weight Kininogens, Thrombosis Research, vol.97, issue.6, pp.481-490, 2000.
DOI : 10.1016/S0049-3848(99)00199-1

A. Kaplan, K. Joseph, Y. Shibayama, Y. Nakazawa, B. Ghebrehiwet et al., Bradykinin formation, Clinical Reviews in Allergy & Immunology, vol.2, issue.1, pp.403-429, 1998.
DOI : 10.1007/BF02737659

D. Proud, C. Baumgarten, R. Naclerio, and P. Ward, Kinin metabolism in human nasal secretions during experimentally induced allergic rhinitis, J. Immunol, vol.138, pp.428-434, 1987.

A. Davis, F. Lu, and P. Mejia, C1 inhibitor, a multi-functional serine protease inhibitor, Thrombosis and Haemostasis, vol.104, issue.5, pp.886-893, 2010.
DOI : 10.1160/TH10-01-0073

A. Ghannam, F. Defendi, D. Charignon, F. Csopaki, B. Favier et al., Contact System Activation in Patients with HAE and Normal C1??Inhibitor Function, Immunology and Allergy Clinics of North America, vol.33, issue.4, pp.513-533, 2013.
DOI : 10.1016/j.iac.2013.07.007

G. Zhou, L. Chao, and J. Chao, Kallistatin: a novel human tissue kallikrein inhibitor. Purification, characterization, and reactive center sequence, J. Biol. Chem, vol.267, pp.25873-25880, 1992.

R. Geiger, U. Stuckstedte, B. Clausnitzer, and H. Fritz, -Protease Inhibitor), Hoppe-Seyler??s Zeitschrift f??r physiologische Chemie, vol.362, issue.1, pp.317-325, 1981.
DOI : 10.1515/bchm2.1981.362.1.317

URL : https://hal.archives-ouvertes.fr/jpa-00210010

M. Cyr, Y. Lepage, C. Blais, N. Gervais, M. Cugno et al., Bradykinin and des-Arg(9)-bradykinin metabolic pathways and kinetics of activation of human plasma, Am. J. Physiol. Heart Circ. Physiol, vol.281, pp.275-83, 2001.

M. Carthy, D. Potter, D. Nicolaides, and E. , An in vivo estimation of the potencies and half-lives of synthetic bradykinin and kallidin, J. Pharmacol. Exp. Ther, vol.148, pp.117-122, 1965.

R. Audet, F. Rioux, G. Drapeau, and F. Marceau, Cardiovascular effects of Sar-[d- Phe8]des-Arg9-Bradykinin, a metabolically protected agonist of B1 receptor for kinins, in the anesthetized rabbit pretreated with a sublethal dose of bacterial lipopolysaccharide, J. Pharmacol. Exp. Ther, vol.280, pp.6-15, 1997.

C. Blais, . Jr, F. Marceau, J. Rouleau, and A. Adam, The kallikrein-kininogen-kinin system: lessons from the quantification of endogenous kinins, Peptides, vol.21, issue.12, 2000.
DOI : 10.1016/S0196-9781(00)00348-X

N. Blaes and J. Girolami, Targeting the ???Janus face' of the B2-bradykinin receptor, Expert Opinion on Therapeutic Targets, vol.24, issue.9, pp.1145-1166, 2013.
DOI : 10.1038/sj.bjp.0706982

G. Molinaro, A. Carmona, M. Juliano, L. Juliano, E. Malitskaya et al., Human recombinant membrane-bound aminopeptidase P: production of a soluble form and characterization using novel, internally quenched fluorescent substrates, Biochemical Journal, vol.385, issue.2, pp.389-397, 2005.
DOI : 10.1042/BJ20040849

W. Nowak, E. Goldschmidt, A. Falcioni, M. Pugliese, A. Errasti et al., Functional evidence of des-Arg10-kallidin enzymatic inactivating pathway in isolated human umbilical vein, Naunyn-Schmiedeberg's Archives of Pharmacology, vol.15, issue.3, pp.221-229, 2007.
DOI : 10.1007/s00210-007-0145-y

P. Ward, A. Chow, and G. Drapeau, Metabolism of bradykinin agonists and antagonists by plasma aminopeptidase P, Biochemical Pharmacology, vol.42, issue.4, pp.721-727, 1991.
DOI : 10.1016/0006-2952(91)90028-4

C. La-corte, A. Carter, A. Rice, G. Duan, Q. Rouleau et al., A functional XPNPEP2 promoter haplotype leads to reduced plasma aminopeptidase P and increased risk of ACE inhibitor-induced angioedema, Human Mutation, vol.23, issue.11, pp.1326-1331, 2011.
DOI : 10.1002/humu.21579

L. Leeb-lundberg, F. Marceau, W. Müller-esterl, D. Pettibone, and B. Zuraw, International Union of Pharmacology. XLV. Classification of the Kinin Receptor Family: from Molecular Mechanisms to Pathophysiological Consequences, Pharmacological Reviews, vol.57, issue.1, pp.27-77, 2005.
DOI : 10.1124/pr.57.1.2

A. Pizard, A. Blaukat, W. Müller-esterl, F. Alhenc-gelas, and R. Rajerison, Bradykinin-induced Internalization of the Human B2Receptor Requires Phosphorylation of Three Serine and Two Threonine Residues at Its Carboxyl Tail, Journal of Biological Chemistry, vol.274, issue.18, pp.12738-12747, 1999.
DOI : 10.1074/jbc.274.18.12738

D. Bachvarov, S. Houle, M. Bachvarova, J. Bouthillier, A. Adam et al., Bradykinin B2 receptor endocytosis, recycling, and down-regulation assessed using green fluorescent protein conjugates, J. Pharmacol. Exp. Ther, vol.297, pp.19-26, 2001.

M. Moreau, N. Garbacki, G. Molinaro, N. Brown, F. Marceau et al., The Kallikrein-Kinin System: Current and Future Pharmacological Targets, Journal of Pharmacological Sciences, vol.99, issue.1, pp.6-38, 2005.
DOI : 10.1254/jphs.SRJ05001X

J. Hess, J. Borkowski, T. Macneil, G. Stonesifer, J. Fraher et al., Differential pharmacology of cloned human and mouse B2 bradykinin receptors, Mol. Pharmacol, vol.45, pp.1-8, 1994.

S. Bastian, B. Loillier, J. Paquet, and D. Pruneau, receptor in 293 cells: pharmacological and functional characterization, British Journal of Pharmacology, vol.277, issue.2, pp.393-399, 1997.
DOI : 10.1038/sj.bjp.0701380

S. Bélanger, V. Bovenzi, J. Côté, W. Neugebauer, M. Amblard et al., Structure???activity relationships of novel peptide agonists of the human bradykinin B2 receptor, Peptides, vol.30, issue.4, pp.777-787, 2009.
DOI : 10.1016/j.peptides.2008.12.003

M. Savard, J. Labonté, C. Dubuc, W. Neugebauer, D. Orléans-juste et al., Further pharmacological evaluation of a novel synthetic peptide bradykinin B2 receptor agonist, Biological Chemistry, vol.394, issue.3, pp.353-360, 2013.
DOI : 10.1515/hsz-2012-0295

K. Bhoola, C. Figueroa, and K. Worthy, Bioregulation of kinins: kallikreins, kininogens, and kininases, Pharmacol. Rev, vol.44, pp.1-80, 1992.

R. Couture, M. Harrisson, R. Vianna, and F. Cloutier, Kinin receptors in pain and inflammation, European Journal of Pharmacology, vol.429, issue.1-3, pp.161-176, 2001.
DOI : 10.1016/S0014-2999(01)01318-8

B. Cassim, G. Mody, and K. Bhoola, Kallikrein cascade and cytokines in inflamed joints, Pharmacology & Therapeutics, vol.94, issue.1-2, pp.1-34, 2002.
DOI : 10.1016/S0163-7258(02)00166-3

S. Meini and C. Maggi, Knee osteoarthritis: a role for bradykinin?, Inflammation Research, vol.57, issue.8, pp.351-361, 2008.
DOI : 10.1007/s00011-007-7204-1

M. Cugno, F. Salerno, M. Mandelli, E. Lorenzano, R. Paonessa et al., Cleavage of high molecular weight kininogen in ascites and plasma of patients with cirrhosis, Thrombosis Research, vol.78, issue.4, pp.277-282, 1995.
DOI : 10.1016/0049-3848(95)00060-5

C. Mansfield, Pathophysiology of Acute Pancreatitis: Potential Application from Experimental Models and Human Medicine to Dogs, Journal of Veterinary Internal Medicine, vol.13, issue.Suppl 1, pp.875-887, 2012.
DOI : 10.1111/j.1939-1676.2012.00949.x

N. Cruden and D. Newby, Therapeutic potential of icatibant (HOE-140

C. Oschatz, C. Maas, B. Lecher, T. Jansen, J. Björkqvist et al., Mast Cells Increase Vascular Permeability by Heparin-Initiated Bradykinin Formation In??Vivo, Immunity, vol.34, issue.2, pp.258-268, 2011.
DOI : 10.1016/j.immuni.2011.02.008

A. Kozik, R. Moore, J. Potempa, T. Imamura, M. Rapala-kozik et al., A Novel Mechanism for Bradykinin Production at Inflammatory Sites. DIVERSE EFFECTS OF A MIXTURE OF NEUTROPHIL ELASTASE AND MAST CELL TRYPTASE VERSUS TISSUE AND PLASMA KALLIKREINS ON NATIVE AND OXIDIZED KININOGENS, Journal of Biological Chemistry, vol.273, issue.50, pp.33224-33229, 1998.
DOI : 10.1074/jbc.273.50.33224

V. Cohan, D. Macglashan, . Jr, J. Warner, L. Lichtenstein et al., Mechanisms of mediator release from human skin mast cells upon stimulation by the bradykinin analog, [dArg0-Hyp3-dPhe7]bradykinin, Biochemical Pharmacology, vol.41, issue.2, pp.293-300, 1991.
DOI : 10.1016/0006-2952(91)90489-R

R. Gulliver, S. Baltic, N. Misso, C. Bertram, P. Thompson et al., ]???Bradykinin Alters Migration and Production of Interleukin-12 in Monocyte-Derived Dendritic Cells, American Journal of Respiratory Cell and Molecular Biology, vol.45, issue.3, pp.542-549, 2011.
DOI : 10.1165/rcmb.2010-0238OC

S. Böckmann and I. Paegelow, Kinins and kinin receptors: importance for the activation of leukocytes, J. Leukoc. Biol, vol.68, pp.587-592, 2000.

E. Sato, S. Koyama, H. Nomura, K. Kubo, and M. Sekiguchi, Bradykinin stimulates alveolar macrophages to release neutrophil, monocyte, and eosinophil chemotactic activity, J. Immunol, vol.157, pp.3122-3129, 1996.

S. Zinner, H. Margolius, B. Rosner, H. Keiser, and E. Kass, FAMILIAL AGGREGATION OF URINARY KALLIKREIN CONCENTRATION IN CHILDHOOD: RELATION TO BLOOD PRESSURE, RACE AND URINARY ELECTROLYTES1, American Journal of Epidemiology, vol.104, issue.2, pp.124-132, 1976.
DOI : 10.1093/oxfordjournals.aje.a112282

R. Fox, R. Goldsmith, D. Kidd, and G. Lewis, Bradykinin as a vasodilator in man, The Journal of Physiology, vol.157, issue.3, pp.589-602, 1961.
DOI : 10.1113/jphysiol.1961.sp006745

M. Marketou and P. Vardas, Bradykinin in the treatment of arterial hypertension: friend or foe?, Hellenic J. Cardiol, vol.53, pp.91-94, 2012.

W. Linz, G. Wiemer, P. Gohlke, T. Unger, and B. Schölkens, Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors, Pharmacol. Rev, vol.47, pp.25-49, 1995.

Y. Kayashima, O. Smithies, and M. Kakoki, The kallikrein???kinin system and oxidative stress, Current Opinion in Nephrology and Hypertension, vol.21, issue.1, pp.92-96, 2012.
DOI : 10.1097/MNH.0b013e32834d54b1

D. Regoli, G. Plante, F. Gobeil, and . Jr, Impact of kinins in the treatment of cardiovascular diseases, Pharmacology & Therapeutics, vol.135, issue.1, pp.94-111, 2012.
DOI : 10.1016/j.pharmthera.2012.04.002

J. Caen and Q. Wu, Hageman factor, platelets and polyphosphates: early history and recent connection, Journal of Thrombosis and Haemostasis, vol.8, issue.Suppl. 1, pp.1670-1674, 2010.
DOI : 10.1111/j.1538-7836.2010.03893.x

H. Bradford, D. Cadena, R. Kunapuli, S. Dong, J. Löpez et al., Human kininogens regulate thrombin binding to platelets through the glycoprotein Ib-IX-V complex, Blood, vol.90, pp.1508-1515, 1997.

T. Renné, A. Schmaier, K. Nickel, M. Blombäck, and C. Maas, In vivo roles of factor XII, Blood, vol.120, issue.22, pp.4296-4303, 2012.
DOI : 10.1182/blood-2012-07-292094

O. Ratnoff and J. Colopy, A FAMILIAL HEMORRHAGIC TRAIT ASSOCIATED WITH A DEFICIENCY OF A CLOT-PROMOTING FRACTION OF PLASMA 1, Journal of Clinical Investigation, vol.34, issue.4, pp.602-613, 1955.
DOI : 10.1172/JCI103109

H. Saito, Studies on Fletcher trait and Fitzgerald trait, Thrombosis and Haemostasis, vol.104, issue.5, pp.867-874, 2010.
DOI : 10.1160/TH10-01-0058

D. Sollo and A. Saleem, Prekallikrein (Fletcher factor) deficiency. Ann, Clin. Lab. Sci, vol.15, pp.279-285, 1985.

R. Woodruff, B. Sullenger, and R. Becker, The many faces of the contact pathway and their role in thrombosis, Journal of Thrombosis and Thrombolysis, vol.49, issue.26, pp.9-20, 2011.
DOI : 10.1007/s11239-011-0578-5

G. Goldsmith, . Jr, H. Saito, and O. Ratnoff, The activation of plasminogen by Hageman factor (Factor XII) and Hageman factor fragments., Journal of Clinical Investigation, vol.62, issue.1, pp.54-60, 1978.
DOI : 10.1172/JCI109113

R. Colman, Activation of plasminogen by human plasma kallikrein, Biochemical and Biophysical Research Communications, vol.35, issue.2, pp.273-279, 1969.
DOI : 10.1016/0006-291X(69)90278-2

N. Brown, J. Gainer, L. Murphey, and D. Vaughan, Bradykinin Stimulates Tissue Plasminogen Activator Release From Human Forearm Vasculature Through B2 Receptor-Dependent, NO Synthase-Independent, and Cyclooxygenase-Independent Pathway, Circulation, vol.102, issue.18, pp.2190-2196, 2000.
DOI : 10.1161/01.CIR.102.18.2190

A. Martins, J. Alves, D. Perez, M. Carrasco, W. Torres-rivera et al., Kinin-B2 Receptor Mediated Neuroprotection after NMDA Excitotoxicity Is Reversed in the Presence of Kinin-B1 Receptor Agonists, PLoS ONE, vol.59, issue.2, p.30755, 2012.
DOI : 10.1371/journal.pone.0030755.s001

C. Duehrkop and R. Rieben, Ischemia/reperfusion injury: Effect of simultaneous inhibition of plasma cascade systems versus specific complement inhibition, Biochemical Pharmacology, vol.88, issue.1, pp.12-22, 2014.
DOI : 10.1016/j.bcp.2013.12.013

C. Mazenot, L. Loufrani, D. Henrion, C. Ribuot, W. Muller-esterl et al., (1)-receptors are induced by myocardial ischaemia-reperfusion in the rabbit, Endothelial kinin B J. Physiol, vol.530, pp.69-78, 2001.

G. Baxter and Z. Ebrahim, Role of bradykinin in preconditioning and protection of the ischaemic myocardium, British Journal of Pharmacology, vol.98, issue.suppl 3A, pp.843-854, 2002.
DOI : 10.1038/sj.bjp.0704548

C. Lagneux, M. Bader, J. Pesquero, P. Demenge, and C. Ribuot, Detrimental implication of B1 receptors in myocardial ischemia: evidence from pharmacological blockade and gene knockout mice, International Immunopharmacology, vol.2, issue.6, pp.815-822, 2002.
DOI : 10.1016/S1567-5769(02)00022-X

V. Danielisová, M. Gottlieb, M. Némethová, and J. Burda, Effects of Bradykinin Postconditioning on Endogenous Antioxidant Enzyme Activity After Transient Forebrain Ischemia in Rat, Neurochemical Research, vol.59, issue.Suppl 1, pp.1057-1064, 2008.
DOI : 10.1007/s11064-007-9550-3

F. Hellal, D. Pruneau, B. Palmier, P. Faye, N. Croci et al., Receptor in a Murine Model of Diffuse Brain Injury, Journal of Neurotrauma, vol.20, issue.9, pp.841-851, 2003.
DOI : 10.1089/089771503322385773

W. Chiang, C. Chien, W. Lin, S. Lin, Y. Chen et al., Early activation of bradykinin B2 receptor aggravates reactive oxygen species generation and renal damage in ischemia/reperfusion injury, Free Radical Biology and Medicine, vol.41, issue.8, pp.1304-1314, 2006.
DOI : 10.1016/j.freeradbiomed.2006.07.011

D. Souza, V. Pinho, J. Pesquero, E. Lomez, S. Poole et al., receptor for the local and systemic inflammatory response that follows severe reperfusion injury, British Journal of Pharmacology, vol.48, issue.1, pp.129-139, 2003.
DOI : 10.1038/sj.bjp.0705200

A. Manolis, M. Marketou, I. Gavras, and H. Gavras, Cardioprotective properties of bradykinin: role of the B2 receptor, Hypertension Research, vol.70, issue.8, pp.772-777, 2010.
DOI : 10.1038/hr.2010.82

M. Austinat, S. Braeuninger, J. Pesquero, M. Brede, M. Bader et al., Blockade of Bradykinin Receptor B1 but Not Bradykinin Receptor B2 Provides Protection From Cerebral Infarction and Brain Edema * Expanded Materials and Methods, Stroke, vol.40, issue.1, pp.285-293, 2009.
DOI : 10.1161/STROKEAHA.108.526673

M. Kakoki and O. Smithies, The kallikrein???kinin system in health and in diseases of the kidney, Kidney International, vol.75, issue.10, pp.1019-1030, 2009.
DOI : 10.1038/ki.2008.647

A. Parenti, L. Morbidelli, F. Ledda, H. Granger, and M. Ziche, The bradykinin/B1 receptor promotes angiogenesis by up-regulation of endogenous FGF-2 in endothelium via the nitric oxide synthase pathway, The FASEB Journal, vol.15, pp.1487-1489, 2001.
DOI : 10.1096/fj.00-0503fje

H. Yu, S. Wang, A. Chang, H. Tai, H. Yeh et al., Bradykinin promotes vascular endothelial growth factor expression and increases angiogenesis in human prostate cancer cells, Biochemical Pharmacology, vol.87, issue.2, pp.243-253, 2014.
DOI : 10.1016/j.bcp.2013.10.016

R. Colman, Y. Wu, and Y. Liu, Mechanisms by which cleaved kininogen inhibits endothelial cell differentiation and signalling, Thrombosis and Haemostasis, vol.104, issue.5, pp.875-885, 2010.
DOI : 10.1160/TH10-01-0017

D. Proud, A. Togias, R. Naclerio, S. Crush, P. Norman et al., Kinins are generated in vivo following nasal airway challenge of allergic individuals with allergen., Journal of Clinical Investigation, vol.72, issue.5, pp.1678-1685, 1983.
DOI : 10.1172/JCI111127

D. Proud and A. Kaplan, Kinin Formation: Mechanisms and Role in Inflammatory Disorders, Annual Review of Immunology, vol.6, issue.1, pp.49-83, 1988.
DOI : 10.1146/annurev.iy.06.040188.000405

M. Marre, P. Bernadet, Y. Gallois, F. Savagner, T. Guyene et al., Relationships Between Angiotensin I Converting Enzyme Gene Polymorphism, Plasma Levels, and Diabetic Retinal and Renal Complications, Diabetes, vol.43, issue.3, pp.384-388, 1994.
DOI : 10.2337/diab.43.3.384

I. Maltais, M. Bachvarova, P. Maheux, P. Perron, F. Marceau et al., receptor gene polymorphism is associated with altered urinary albumin/creatinine values in diabetic patients, Canadian Journal of Physiology and Pharmacology, vol.80, issue.4, pp.323-327, 2002.
DOI : 10.1139/y02-036

O. Zaika, M. Mamenko, O. Neil, R. Pochynyuk, and O. , Bradykinin acutely inhibits activity of the epithelial Na+ channel in mammalian aldosterone-sensitive distal nephron, AJP: Renal Physiology, vol.300, issue.5, pp.1105-1115, 2011.
DOI : 10.1152/ajprenal.00606.2010

S. Sivritas, D. Ploth, and W. Fitzgibbon, Blockade of renal medullary bradykinin B2 receptors increases tubular sodium reabsorption in rats fed a normal-salt diet, AJP: Renal Physiology, vol.295, issue.3, pp.811-817, 2008.
DOI : 10.1152/ajprenal.90225.2008

E. Kashuba, J. Bailey, D. Allsup, and L. Cawkwell, The kinin???kallikrein system: physiological roles, pathophysiology and its relationship to cancer biomarkers, Biomarkers, vol.286, issue.4, pp.279-296, 2013.
DOI : 10.1080/02688690500305555

J. Wu, T. Akaike, K. Hayashida, Y. Miyamoto, T. Nakagawa et al., Identification of bradykinin receptors in clinical cancer specimens and murine tumor tissues, International Journal of Cancer, vol.63, issue.suppl, pp.29-35, 2002.
DOI : 10.1002/ijc.10142

H. Maeda, Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting, Proceedings of the Japan Academy, Series B, vol.88, issue.3, pp.53-71, 2012.
DOI : 10.2183/pjab.88.53

C. Beck, G. Piontek, A. Haug, M. Bas, A. Knopf et al., The kallikrein???kinin-system in head and neck squamous cell carcinoma (HNSCC) and its role in tumour survival, invasion, migration and response to radiotherapy, Oral Oncology, vol.48, issue.12, pp.1208-1219, 2012.
DOI : 10.1016/j.oraloncology.2012.06.001

I. Duka, S. Shenouda, C. Johns, E. Kintsurashvili, I. Gavras et al., Role of the B2 Receptor of Bradykinin in Insulin Sensitivity, Hypertension, vol.38, issue.6, pp.1355-1360, 2001.
DOI : 10.1161/hy1201.096574

E. Henriksen and S. Jacob, Angiotensin converting enzyme inhibitors and modulation of skeletal muscle insulin resistance, Diabetes, Obesity and Metabolism, vol.41, issue.4, pp.214-222, 2003.
DOI : 10.1016/S0895-7061(99)00174-0

D. Campbell, D. Kelly, J. Wilkinson-berka, M. Cooper, and S. Skinner, Increased bradykinin and ???normal??? angiotensin peptide levels in diabetic Sprague-Dawley and transgenic (mRen-2)27 rats, Kidney International, vol.56, issue.1, pp.211-221, 1999.
DOI : 10.1046/j.1523-1755.1999.00519.x

R. Catalioto, C. Valenti, L. Liverani, S. Giuliani, and C. Maggi, Characterization of a novel proinflammatory effect mediated by BK and the kinin B2 receptor in human preadipocytes, Biochemical Pharmacology, vol.86, issue.4, pp.508-520, 2013.
DOI : 10.1016/j.bcp.2013.06.005

R. Fonseca, V. Sales, E. Ropelle, C. Barros, L. Oyama et al., Lack of kinin B1 receptor potentiates leptin action in the liver, Journal of Molecular Medicine, vol.92, issue.7, pp.851-860, 2013.
DOI : 10.1007/s00109-013-1004-6

Y. Okada, Y. Tuchiya, M. Yagyu, S. Kozawa, and K. Kariya, Synthesis of bradykinin fragments and their effect on pentobarbital sleeping time in mouse, Neuropharmacology, vol.16, issue.5, pp.381-383, 1977.
DOI : 10.1016/0028-3908(77)90076-4

K. Kariya and A. Yamauchi, Effects of intraventricular injection of bradykinin on the EEG and the blood pressure in conscious rats, Neuropharmacology, vol.20, issue.12, pp.1221-1224, 1981.
DOI : 10.1016/0028-3908(81)90068-X

E. Thornton, J. Ziebell, A. Leonard, and R. Vink, Kinin Receptor Antagonists as Potential Neuroprotective Agents in Central Nervous System Injury, Molecules, vol.15, issue.9, pp.6598-6618, 2010.
DOI : 10.3390/molecules15096598

K. Joseph, Y. Shibayama, Y. Nakazawa, E. Peerschke, B. Ghebrehiwet et al., Interaction of Factor XII and high molecular weight kininogen with cytokeratin 1 and gC1qR of vascular endothelial cells and with aggregated A?? protein of Alzheimer's disease, Immunopharmacology, vol.43, issue.2-3, pp.203-210, 1999.
DOI : 10.1016/S0162-3109(99)00136-8

E. Ashby, S. Love, and P. Kehoe, Assessment of activation of the plasma kallikrein-kinin system in frontal and temporal cortex in Alzheimer's disease and vascular dementia, Neurobiology of Aging, vol.33, issue.7, pp.1345-1355, 2012.
DOI : 10.1016/j.neurobiolaging.2010.09.024

E. Whalley, S. Clegg, J. Stewart, and R. Vavrek, The effect of kinin agonists and antagonists on the pain response of the human blister base, Naunyn-Schmiedeberg's Archives of Pharmacology, vol.336, issue.6, pp.652-655, 1987.
DOI : 10.1007/BF00165756

J. Ferreira, A. Beirith, M. Mori, R. Araújo, M. Bader et al., Reduced Nerve Injury-Induced Neuropathic Pain in Kinin B1 Receptor Knock-Out Mice, Journal of Neuroscience, vol.25, issue.9, pp.2405-2412, 2005.
DOI : 10.1523/JNEUROSCI.2466-04.2005

D. Campos, R. Henriques, M. Calixto, and J. , Systemic treatment with Mycobacterium bovis bacillus calmette-guerin (BCG) potentiates kinin B1 receptor agonist-induced nociception and oedema formation in the formalin test in mice, Neuropeptides, vol.32, issue.5, pp.393-403, 1998.
DOI : 10.1016/S0143-4179(98)90062-2

P. Green, J. Luo, P. Heller, and J. Levine, Modulation of bradykinin-induced plasma extravasation in the rat knee joint by sympathetic co-transmitters, Neuroscience, vol.52, issue.2, pp.451-458, 1993.
DOI : 10.1016/0306-4522(93)90171-B

K. Walker, M. Perkins, and A. Dray, Kinins and kinin receptors in the nervous system, Neurochemistry International, vol.26, issue.1, pp.1-16, 1995.
DOI : 10.1016/0197-0186(94)00114-A

F. Defendi, D. Charignon, A. Ghannam, R. Baroso, F. Csopaki et al., Enzymatic Assays for the Diagnosis of Bradykinin-Dependent Angioedema, PLoS ONE, vol.61, issue.8, p.70140, 2013.
DOI : 10.1371/journal.pone.0070140.s001

F. Defendi, D. Charignon, F. Csopaki, D. Ponard, and C. Drouet, Actualit??s biologiques sur les angioed??mes ?? kinines, Revue Francophone des Laboratoires, vol.2012, issue.444, pp.39-52, 2012.
DOI : 10.1016/S1773-035X(12)71616-7

A. López-lera, S. Garrido, O. Roche, and M. López-trascasa, SERPING1 mutations in 59 families with hereditary angioedema, Molecular Immunology, vol.49, issue.1-2, pp.18-27, 2011.
DOI : 10.1016/j.molimm.2011.07.010

L. Bouillet-claveyrolas, D. Ponard, C. Drouet, and C. Massot, Clinical and biological distinctions between type I and type II acquired angioedema, The American Journal of Medicine, vol.115, issue.5, pp.420-421, 2003.
DOI : 10.1016/S0002-9343(03)00396-6

Q. Duan, B. Nikpoor, M. Dube, G. Molinaro, I. Meijer et al., A Variant in XPNPEP2 Is Associated with Angioedema Induced by Angiotensin I???Converting Enzyme Inhibitors, The American Journal of Human Genetics, vol.77, issue.4, pp.617-626, 2005.
DOI : 10.1086/496899

H. Cao and R. Hegele, DNA polymorphism and mutations in CPN1 , including the genomic basis of carboxypeptidase N deficiency, Journal of Human Genetics, vol.48, issue.1, pp.20-22, 2003.
DOI : 10.1007/s100380300003

J. Roberts, J. Lee, and D. Marthers, Angiotensin-Converting Enzyme (ACE) Inhibitor Angioedema: The Silent Epidemic, The American Journal of Cardiology, vol.109, issue.5, pp.774-775, 2012.
DOI : 10.1016/j.amjcard.2011.11.014

S. Toh and . Rm, Comparative Risk for Angioedema Associated With the Use of Drugs That Target the Renin-Angiotensin-Aldosterone System, Archives of Internal Medicine, vol.172, issue.20, pp.1582-1589, 2012.
DOI : 10.1001/2013.jamainternmed.34

N. Brown, S. Byiers, D. Carr, M. Maldonado, and B. Warner, Dipeptidyl Peptidase-IV Inhibitor Use Associated With Increased Risk of ACE Inhibitor-Associated Angioedema, Hypertension, vol.54, issue.3, pp.516-523, 2009.
DOI : 10.1161/HYPERTENSIONAHA.109.134197

A. Adam, M. Cugno, G. Molinaro, M. Perez, Y. Lepage et al., Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors, The Lancet, vol.359, issue.9323, pp.2088-2089, 2002.
DOI : 10.1016/S0140-6736(02)08914-6

B. Ritchie, Protease inhibitors in the treatment of hereditary angioedema, Transfusion and Apheresis Science, vol.29, issue.3, pp.259-267, 2003.
DOI : 10.1016/j.transci.2003.08.004

M. Levi, G. Choi, C. Picavet, and C. Hack, Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency, Journal of Allergy and Clinical Immunology, vol.117, issue.4, pp.904-908, 2006.
DOI : 10.1016/j.jaci.2006.01.002

D. Regoli, J. Barabé, and W. Park, Receptors for bradykinin in rabbit aortae, Canadian Journal of Physiology and Pharmacology, vol.55, issue.4, pp.855-867, 1977.
DOI : 10.1139/y77-115

N. Rhaleb, S. Telemaque, N. Rouissi, S. Dion, D. Jukic et al., Structure-activity studies of bradykinin and related peptides. B2- receptor antagonists, Hypertension, vol.17, issue.1, pp.107-115, 1991.
DOI : 10.1161/01.HYP.17.1.107

D. Sawutz, J. Salvino, R. Dolle, F. Casiano, S. Ward et al., The nonpeptide WIN 64338 is a bradykinin B2 receptor antagonist., Proc. Natl. Acad
DOI : 10.1073/pnas.91.11.4693

M. Altamura, S. Meini, L. Quartara, and C. Maggi, Nonpeptide antagonists for kinin receptors, Regulatory Peptides, vol.80, issue.1-2, pp.13-26, 1999.
DOI : 10.1016/S0167-0115(99)00003-8

T. Griesbacher and F. Legat, Effects of the non-peptide B 2 receptor antagonist FR173657 in models of visceral and cutaneous inflammation, Inflammation Research, vol.49, issue.10, pp.535-540, 2000.
DOI : 10.1007/s000110050628

F. Marceau, L. Levesque, G. Drapeau, F. Rioux, J. Salvino et al., Effects of peptide and nonpeptide antagonists of bradykinin B2 receptors on the venoconstrictor action of bradykinin, J. Pharmacol. Exp. Ther, vol.269, pp.1136-1143, 1994.

D. Pruneau, J. Luccarini, C. Fouchet, E. Defrêne, R. Franck et al., 0335, a novel potent and selective nonpeptide antagonist of the human bradykinin B2 receptor, Br. J. Pharmacol, vol.16125, pp.365-372, 1998.

D. Pruneau, J. Paquet, J. Luccarini, E. Defrêne, C. Fouchet et al., Pharmacological profile of LF 16-0687, a new potent non-peptide bradykinin B2 receptor antagonist, Immunopharmacology, vol.43, issue.2-3, pp.187-194, 1999.
DOI : 10.1016/S0162-3109(99)00128-9

F. Marceau, J. Fortin, G. Morissette, and E. Dziadulewicz, A non-peptide antagonist unusually selective for the human form of the bradykinin B2 receptor, International Immunopharmacology, vol.3, issue.10-11, pp.1529-1536, 2003.
DOI : 10.1016/S1567-5769(03)00180-2

F. Hock, K. Wirth, U. Albus, W. Linz, H. Gerhards et al., Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies, British Journal of Pharmacology, vol.10, issue.Suppl. 1, pp.769-773, 1991.
DOI : 10.1111/j.1476-5381.1991.tb12248.x

M. Félétou, M. Germain, C. Thurieau, J. Fauchère, and E. Canet, Agonistic and antagonistic properties of the bradykinin B2 receptor antagonist, Hoe 140, in isolated blood vessels from different species, British Journal of Pharmacology, vol.102, issue.Suppl. 6, pp.683-689, 1994.
DOI : 10.1111/j.1476-5381.1994.tb13130.x

K. Jarnagin, S. Bhakta, P. Zuppan, C. Yee, T. Ho et al., Mutations in the B2 Bradykinin Receptor Reveal a Different Pattern of Contacts for Peptidic Agonists and Peptidic Antagonists, Journal of Biological Chemistry, vol.271, issue.45, pp.28277-28286, 1996.
DOI : 10.1074/jbc.271.45.28277

N. Rhaleb, N. Rouissi, D. Jukic, D. Regoli, S. Henke et al., Pharmacological characterization of a new highly potent B2 receptor antagonist, HOE Eur. J. Pharmacol, vol.140210, issue.83, pp.115-120, 1992.

F. Lembeck, T. Griesbacher, M. Eckhardt, S. Henke, G. Breipohl et al., New, long-acting, potent bradykinin antagonists, British Journal of Pharmacology, vol.6, issue.2, pp.297-304, 1991.
DOI : 10.1111/j.1476-5381.1991.tb12169.x

M. Félétou, C. Martin, M. Molimard, E. Naline, M. Germain et al., In vitro effects of HOE 140 in human bronchial and vascular tissue, European Journal of Pharmacology, vol.274, issue.1-3, pp.57-64, 1995.
DOI : 10.1016/0014-2999(94)00709-G

K. Wirth, F. Hock, U. Albus, W. Linz, H. Alpermann et al., Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies, British Journal of Pharmacology, vol.111, issue.3, pp.774-777, 1991.
DOI : 10.1111/j.1476-5381.1991.tb12249.x

J. Damas and G. Remacle-volon, Influence of a long-acting bradykinin antagonist, Hoe 140, on some acute inflammatory reactions in the rat, European Journal of Pharmacology, vol.211, issue.1, pp.81-86, 1992.
DOI : 10.1016/0014-2999(92)90266-7

T. Sakamoto, W. Elwood, P. Barnes, and K. Chung, Effect of Hoe 140, a new bradykinin receptor antagonist, on bradykinin- and platelet-activating factor-induced bronchoconstriction and airway microvascular leakage in guinea pig, European Journal of Pharmacology, vol.213, issue.3, pp.367-373, 1992.
DOI : 10.1016/0014-2999(92)90625-E

K. Wirth, D. Gehring, and B. Scholkens, Effect of Hoe 140 on Bradykinin-induced Bronchoconstriction in Anesthetized Guinea Pigs, American Review of Respiratory Disease, vol.148, issue.3, pp.702-706, 1993.
DOI : 10.1164/ajrccm/148.3.702

J. Cockcroft, P. Chowienczyk, S. Brett, N. Bender, and J. Ritter, Inhibition of bradykinin-induced vasodilation in human forearm vasculature by icatibant, a potent B2-receptor antagonist., British Journal of Clinical Pharmacology, vol.11, issue.suppl 4, pp.317-321, 1994.
DOI : 10.1111/j.1365-2125.1994.tb04360.x

I. Squire, O. Kane, K. Anderson, N. Reid, and J. , Bradykinin B2 Receptor Antagonism Attenuates Blood Pressure Response to Acute Angiotensin-Converting Enzyme Inhibition in Normal Men, Hypertension, vol.36, issue.1, pp.132-136, 2000.
DOI : 10.1161/01.HYP.36.1.132

K. Bork, J. Frank, B. Grundt, P. Schlattmann, J. Nussberger et al., Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant), Journal of Allergy and Clinical Immunology, vol.119, issue.6, pp.1497-1503, 2007.
DOI : 10.1016/j.jaci.2007.02.012

M. Cicardi, A. Banerji, F. Bracho, A. Malbrán, B. Rosenkranz et al., Icatibant, a New Bradykinin-Receptor Antagonist, in Hereditary Angioedema, New England Journal of Medicine, vol.363, issue.6, pp.532-541, 2010.
DOI : 10.1056/NEJMoa0906393

T. Bowen, M. Cicardi, H. Farkas, K. Bork, H. Longhurst et al., 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema, Allergy, Asthma & Clinical Immunology, vol.6, issue.1, p.24, 2010.
DOI : 10.1186/1710-1492-6-24

W. Lumry, H. Li, R. Levy, P. Potter, H. Farkas et al., Randomized placebo-controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial, Annals of Allergy, Asthma & Immunology, vol.107, issue.6, pp.529-537, 2011.
DOI : 10.1016/j.anai.2011.08.015

M. Maurer and M. Church, Inflammatory skin responses induced by icatibant injection are mast cell mediated and attenuated by H1-antihistamines, Experimental Dermatology, vol.261, issue.11, pp.154-159, 2012.
DOI : 10.1111/j.1600-0625.2011.01410.x

A. Charmillon, J. Deibener, P. Kaminsky, and G. Louis, Angioedema induced by angiotensin converting enzyme inhibitors, potentiated by m-TOR inhibitors: successful treatment with icatibant, Intensive Care Medicine, vol.40, issue.6, 2014.
DOI : 10.1007/s00134-014-3290-z

L. Bouillet, I. Boccon-gibod, D. Ponard, C. Drouet, J. Cesbron et al., BRADYKININ RECEPTOR 2 ANTAGONIST (ICATIBANT) FOR HEREDITARY ANGIOEDEMA TYPE III ATTACKS, Annals of Allergy, Asthma & Immunology, vol.103, issue.5, p.448, 2009.
DOI : 10.1016/S1081-1206(10)60369-9

URL : https://hal.archives-ouvertes.fr/hal-00474261

M. Bas, J. Greve, K. Stelter, H. Bier, T. Stark et al., Therapeutic Efficacy of Icatibant in Angioedema Induced by Angiotensin-Converting Enzyme Inhibitors: A Case Series, Annals of Emergency Medicine, vol.56, issue.3, pp.278-282, 2010.
DOI : 10.1016/j.annemergmed.2010.03.032

L. Marqués, D. Domingo, F. Maravall, and J. Clotet, Short-term prophylactic treatment of hereditary angioedema with icatibant, Allergy, vol.119, issue.1, pp.137-138, 2010.
DOI : 10.1111/j.1398-9995.2009.02160.x

K. Senaratne, A. Cottrell, and R. Prentice, Successful perioperative management of a patient with C1 esterase inhibitor deficiency with a novel bradykinin receptor B2 antagonist, Anaesth. Intensive Care, vol.40, pp.523-526, 2012.

W. Aberer, M. Maurer, A. Reshef, H. Longhurst, S. Kivity et al., Openlabel , multicenter study of self-administered icatibant for attacks of hereditary angioedema, Allergy, 2013.

M. Maurer, W. Aberer, L. Bouillet, T. Caballero, V. Fabien et al., Hereditary Angioedema Attacks Resolve Faster and Are Shorter after Early Icatibant Treatment, PLoS ONE, vol.104, issue.2, p.53773, 2013.
DOI : 10.1371/journal.pone.0053773.s001

M. Cugno, J. Nussberger, P. Biglioli, M. Giovagnoni, M. Gardinali et al., Cardiopulmonary bypass increases plasma bradykinin concentrations, Immunopharmacology, vol.43, issue.2-3, pp.145-147, 1999.
DOI : 10.1016/S0162-3109(99)00072-7

J. Balaguer, C. Yu, J. Byrne, S. Ball, M. Petracek et al., Contribution of Endogenous Bradykinin to Fibrinolysis, Inflammation, and Blood Product Transfusion Following Cardiac Surgery: A Randomized Clinical Trial, Clinical Pharmacology & Therapeutics, vol.86, issue.4, pp.326-334, 2013.
DOI : 10.1161/hy0302.105767

C. Pedersen, M. Schmidt, G. Barnes, H. Bøtker, R. Kharbanda et al., Bradykinin does not mediate remote ischaemic preconditioning or ischaemia-reperfusion injury in vivo in man, Heart, vol.97, issue.22, pp.1857-1861, 2011.
DOI : 10.1136/heartjnl-2011-300323

D. Falco, L. Fioravanti, A. Galeazzi, M. Tenti, and S. , Bradykinin and its role in osteoarthritis, Reumatismo, vol.65, issue.3, pp.97-104, 2013.
DOI : 10.4081/reumatismo.2013.97

I. Song, C. Althoff, K. Hermann, A. Scheel, T. Knetsch et al., Contrast-enhanced ultrasound in monitoring the efficacy of a bradykinin receptor 2 antagonist in painful knee osteoarthritis compared with MRI, Annals of the Rheumatic Diseases, vol.68, issue.1, pp.75-83, 2009.
DOI : 10.1136/ard.2007.080382

D. Proud, J. Bathon, A. Togias, and R. Naclerio, Inhibition of the response to nasal provocation with bradykinin by HOE- 140: efficacy and duration of action, Canadian Journal of Physiology and Pharmacology, vol.73, issue.7, pp.820-826, 1995.
DOI : 10.1139/y95-111

C. Austin, J. Foreman, and G. Scadding, Reduction by Hoe 140, the B2 kinin receptor antagonist, of antigen-induced nasal blockage, British Journal of Pharmacology, vol.85, issue.4, pp.969-971, 1994.
DOI : 10.1111/j.1476-5381.1994.tb14835.x

P. Turner, J. Dear, G. Scadding, and J. Foreman, Role of kinins in seasonal allergic rhinitis: Icatibant, a bradykinin B2 receptor antagonist, abolishes the hyperresponsiveness and nasal eosinophilia induced by antigen, Journal of Allergy and Clinical Immunology, vol.107, issue.1, pp.105-113, 2001.
DOI : 10.1067/mai.2001.111145

B. Rosenkranz, K. Bork, J. Frank, W. Kreuz, L. Dong et al., Proof-of-concept study of icatibant (JE 049), a bradykinin B2 receptor antagonist in treatment of hereditary angioedema, Clinical Pharmacology & Therapeutics, vol.77, issue.2, p.14, 2005.
DOI : 10.1016/j.clpt.2004.11.055

A. Akbary, K. Wirth, and B. Schölkens, Efficacy and tolerability of Icatibant (Hoe 140) in patients with moderately severe chronic bronchial asthma, Immunopharmacology, vol.33, issue.1-3, pp.238-242, 1996.
DOI : 10.1016/0162-3109(96)00065-3

J. Antonen, I. Leppänen, J. Tenhunen, P. Arvola, S. Mäkelä et al., A severe case of Puumala hantavirus infection successfully treated with bradykinin receptor antagonist icatibant. Scand, J. Infect. Dis, vol.45, pp.494-496, 2013.

Y. Nagao, H. Harada, H. Yamanaka, and K. Fukuda, Possible Mediators for Systemic Capillary Leak Syndrome, The American Journal of Medicine, vol.124, issue.1, pp.7-9, 2011.
DOI : 10.1016/j.amjmed.2010.04.024

D. Levy and D. Zochodne, Increased mRNA expression of the B1 and B2 bradykinin receptors and antinociceptive effects of their antagonists in an animal model of neuropathic pain, Pain, vol.86, issue.3, pp.265-271, 2000.
DOI : 10.1016/S0304-3959(00)00256-6

R. Prediger, R. Medeiros, P. Pandolfo, F. Duarte, G. Passos et al., Genetic deletion or antagonism of kinin B1 and B2 receptors improves cognitive deficits in a mouse model of Alzheimer's disease, Neuroscience, vol.151, issue.3, pp.631-643, 2008.
DOI : 10.1016/j.neuroscience.2007.11.009

A. Fein, G. Bernard, G. Criner, E. Fletcher, J. Good et al., Treatment of Severe Systemic Inflammatory Response Syndrome and Sepsis With a Novel Bradykinin Antagonist, Deltibant (CP-0127)<subtitle>Results of a Randomized, Double-blind, Placebo-Controlled Trial</subtitle>, JAMA: The Journal of the American Medical Association, vol.277, issue.6, pp.482-487, 1997.
DOI : 10.1001/jama.1997.03540300050033

O. Shaw and J. Harper, Bradykinin receptor 2 extends inflammatory cell recruitment in a model of acute gouty arthritis, Biochemical and Biophysical Research Communications, vol.416, issue.3-4, pp.266-269, 2011.
DOI : 10.1016/j.bbrc.2011.10.137

T. Griesbacher, R. I. Evans, and D. , Inhibition of kinin action and kinin generation compared to dexamethasone pretreatment with respect to vascular effects and pancreatic enzymes in experimental acute pancreatitis, Immunopharmacology, vol.43, issue.2-3, pp.219-224, 1999.
DOI : 10.1016/S0162-3109(99)00093-4

J. Stewart, Bradykinin antagonists: Development and applications, Biopolymers, vol.269, issue.2, pp.143-155, 1995.
DOI : 10.1002/bip.360370208

F. Bossi, F. Fischetti, D. Regoli, P. Durigutto, B. Frossi et al., Novel pathogenic mechanism and therapeutic approaches to angioedema associated with C1 inhibitor deficiency, Journal of Allergy and Clinical Immunology, vol.124, issue.6, pp.1303-1310, 2009.
DOI : 10.1016/j.jaci.2009.08.007

J. Greve, T. Hoffmann, P. Schuler, S. Lang, A. Chaker et al., Successful long-term treatment with the bradykinin B2 receptor antagonist icatibant in a patient with hereditary angioedema, International Journal of Dermatology, vol.8, issue.10, pp.1294-1295, 2011.
DOI : 10.1111/j.1365-4632.2011.05051.x

F. Bossi, F. Fischetti, V. Pellis, R. Bulla, E. Ferrero et al., Platelet-Activating Factor and Kinin-Dependent Vascular Leakage as a Novel Functional Activity of the Soluble Terminal Complement Complex, The Journal of Immunology, vol.173, issue.11, pp.6921-6927, 2004.
DOI : 10.4049/jimmunol.173.11.6921

D. Bouïs, G. Hospers, C. Meijer, G. Molema, and N. Mulder, Endothelium in vitro: a review of human vascular endothelial cell lines for blood vessel-related research, Angiogenesis, vol.4, issue.2, pp.91-102, 2001.
DOI : 10.1023/A:1012259529167

A. Brechter, E. Persson, I. Lundgren, and U. Lerner, Kinin B1 and B2 receptor expression in osteoblasts and fibroblasts is enhanced by interleukin-1 and tumour necrosis factor-??. Effects dependent on activation of NF-??B and MAP kinases, Bone, vol.43, issue.1, pp.72-83, 2008.
DOI : 10.1016/j.bone.2008.02.003

A. Charignon, D. Späth, P. Martin, L. Drouet, and C. , Icatibant, the bradykinin B2 receptor antagonist with target to the interconnected kinin systems, Expert Opinion on Pharmacotherapy, vol.9, issue.15, pp.2233-2280, 2012.
DOI : 10.3390/molecules15096598